IL17A and inflammatory bowel disease: The severity of IBD peaked at 6 days after colitis induction, ndSTAT1-TMD, ndSTAT1-TMD (V426D, T427D), or anti-IL-17A antibody treatment was initiated on day 6 through intraperitoneal injection.